Clinical manifestations

Presentation and course

Folate transport disorders. Cerebral folate deficiency can be produced by a specific transport defect resulting in decreased folate transport across the blood-brain barrier at the choroid plexus. This may be caused either by folate receptor alpha deficiency resulting from mutations of the FOLR1 encoding gene with an autosomal-recessive transmission pattern or by the production of blocking/binding autoantibodies.

Patients with genetic forms of cerebral folate deficiency typically present with developmental delay, seizures, abnormal movements, and delayed myelination (29).

Age of clinical onset of folate receptor alpha deficiency varies, but in most cases, the disorder presents as an encephalopathy during the first year of life after an initial period of normal motor development (48). Early signs of the disorder may include agitation and sleep disturbances. Affected individuals show deceleration of head growth and psychomotor delay or regression that can develop into severe retardation in the absence of treatment. Hypotonia, dyskinesia, spasticity, and ataxia may be present (30; 14). There may also be visual disturbances leading to visual loss and optic atrophy in the absence of treatment, and some children exhibit progressive hearing loss starting at about 6 years of age. Seizures (ie, myoclonic, tonic, astatic, generalized tonic-clonic) are typical, with myoclonic seizures being the most frequent seizure type; these may be intractable (35; 17; 27; 05; 26; 48; 13; 16; 41; 49; 14; 21; 24; 22; 19). Infantile spasms and status epilepticus have also been reported (47). Several children have had autistic features (27; 26; 15; 33; 19). On neuroimaging, untreated children have shown moderate frontotemporal atrophy with signs of periventricular and subcortical demyelination or hypomyelination and slowly progressive supra- and infratentorial atrophy (35; 21). A peripheral neuropathy with axonal degeneration and demyelinating features has also been reported (21).

Patients with cerebral folate deficiency associated with blocking autoantibodies against folate receptor alpha may present at a later age with autism or schizophrenia that is unresponsive to conventional treatment (39; 36; 43; 42; 18; 12; 33; 31) or with myoclonus and memory impairment (46). A 13-year-old previously healthy boy presented with a 17-month history of schizophrenic symptoms with progressively worsening catatonia, near-complete mutism, frequent enuresis and encopresis, and severe psychomotor retardation (18). A 58-year-old woman with folate receptor alpha autoimmunity presented with mild myoclonus and short-term memory impairment (46).

Patients with genetic forms of cerebral folate deficiency may present with other genetic disorders in nearby areas on chromosome 11. For example, a boy presented with congenital deafness, hypotonia, and ataxia in early childhood (13). At age 6, he developed intractable epilepsy. He deteriorated clinically, and at age 8 he developed respiratory arrest and severe hypercapnia. He had homozygous nonsense mutations in the FOLR1 gene and FGF3 gene, both of which map to 11q13. The latter mutation caused congenital deafness with labyrinthine aplasia, microtia, and microdontia (LAMM syndrome).

Disorders of folate metabolism. Methylenetetrahydrofolate reductase deficiency is the most frequent inborn error of folate metabolism, with more than 200 patients reported in the literature (07; 32). The wide phenotypic spectrum ranges from severe neurologic deterioration and early death in infancy to asymptomatic adults. Hematological signs include megaloblastic anemia or pancytopenia. Neurologic presentations of severe methylenetetrahydrofolate deficiency include early-onset cases presenting in the first months of life with intractable seizures, epileptic encephalopathy, apnea, and hydrocephalus, and later-onset cases presenting with neurologic regression, ataxia, seizures, cerebral atrophy, and delayed myelination (32). Clinical manifestations in older children and adults include intellectual disability, recurrent cerebrovascular occlusion, psychiatric manifestations, and cerebral white matter abnormalities.

Clinical signs of dihydrofolate reductase deficiency include severe megaloblastic anemia or pancytopenia, microcephaly (and cerebral and cerebellar atrophy), and refractory seizures (04; 09; 32).

Clinical signs of methenyl-tetrahydrofolate synthase deficiency include microcephaly, epilepsy, and hypomyelination (45; 32).

Prognosis and complications

Prognosis and complications vary across the disorders of folate transport and metabolism.

Biological basis

Etiology and pathogenesis

Folate, an essential micronutrient, is a critical cofactor in one-carbon metabolism. Humans and other mammals cannot synthesize folate and depend on dietary sources to maintain normal levels (03).

Folate transport disorders. Cerebral folate deficiency can result from decreased function of folate receptor alpha, which, together with the proton-coupled folate receptor, is required for transport of folate (mainly as MTHF) across the blood-brain barrier at the choroid plexus (52; 02; 51; 32).

Two causes have been identified: some patients have an autosomal recessive disorder resulting from mutations in the FOLR1 gene, which encodes folate receptor alpha (48; 16); other patients have blocking autoantibodies directed against folate receptor alpha (39; 05; 38).

The fundamental characteristic of these disorders is a specific inability to transport folate from the blood to the central nervous system, resulting in decreased CSF MTHF concentrations in the presence of normal blood folate concentrations. This contrasts with hereditary folate malabsorption or dietary folate deficiency where both blood and CSF folate concentrations are decreased (51). Antibodies against folate receptor alpha may play a role in cerebral folate deficiency in individuals with Rett syndrome and a form of Aicardi-Goutieres syndrome (41).

Mutations in the FOLR1 gene on chromosome 11q13.4 have been identified in more than 20 families (32).

To date, various mutations have been identified, including nonsense, missense, splice-site mutations, and insertion mutations (08; 48; 30; 13; 28; 16; 01).

Disorders of folate metabolism.

Methylenetetrahydrofolate reductase deficiency is an autosomal recessive disorder caused by mutations in the MTHFR gene on chromosome 1. The cytogenetic location of the MTHFR gene is 1p36.22.

MTHFR catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the essential methyl group donor for remethylation of homocysteine to methionine (so consequently, key biochemical changes associated with this disorder include elevated plasma total homocysteine and low methionine levels) (50).

Dihydrofolate reductase deficiency is an autosomal recessive disorder caused by homozygous mutation in the DHFR gene on chromosome 5q. The cytogenetic location of the DHFR gene is 5q14.1.

DHFR converts dihydrofolate into tetrahydrofolate, a methyl group shuttle required for de novo synthesis of purines, thymidylic acid, and some amino acids.

Methenyltetrahydrofolate synthetase deficiency is an autosomal recessive disorder caused by mutations in the MTHFS gene on chromosome 15. The cytogenetic location of the DHFR gene is 15q25.1.

5,10-MTHFS catalyzes the ATP-dependent conversion of folinic acid (5-formyltetrahydrofolate, 5-FTHF) to 5,10-methenyltetrahydrofolate (5,10-MTHF) (10). 5,10-methenyltetrahydrofolate is then converted to either 5,10-methylene-tetrahydrofolate, the precursor of 5-MTHF, or 10-formyltetrahydrofolate, which is important for purine metabolism.

Epidemiology

Prevalence of cerebral folate deficiency is estimated to be between 1/4000 and 1/6000 children, although the disorder is probably underdiagnosed (41). More than 20 affected children have been reported with FOLR1 mutations (32). Methylenetetrahydrofolate reductase deficiency is the most frequent inborn error of folate metabolism, with more than 200 patients reported in the literature (07; 32). Dihydrofolate reductase deficiency appears to be very rare: six individuals were described from three families in 2011, but no cases have been reported since then (04; 09; 32). Two unrelated boys have been reported with methenyltetrahydrofolate synthetase deficiency (45).

Prevention

Prevention is not possible; early diagnosis before development of severe neurologic problems appears vital.

Differential diagnosis

Confusing conditions

Cerebral folate deficiency is characterized by decreased folate (MTHF) concentration in the CSF (less than 40 nmol/L) in the presence of normal blood folate concentrations. Cerebral folate deficiency from cerebral folate transport defects can be confirmed by identifying antibodies to folate receptor alpha (although this test is not commonly available) or by detecting mutations in FOLR1. Cerebral folate concentrations are extremely low (less than 5 nmol/L) in individuals with FOLR1 mutations (16; 32).

Decreased concentrations of folate in the CSF also may be seen in several other neurologic disorders, including with Rett syndrome, Aicardi-Goutières syndrome, 3-phosphoglcerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, Kearns-Sayre syndrome, and mitochondrial complex I encephalomyopathy, as well as with chronic exposure to antifolate drugs or anticonvulsant medications (35; 34).

Diagnostic workup

Early diagnosis is crucial because high-dose folinic acid is an effective treatment that can ameliorate or even prevent further neurodegeneration (14).

The following diagnostic procedures are required to establish the diagnosis of cerebral folate deficiency and rule out alternatives:

Neuroradiological findings in patients with cerebral folate deficiency may include delayed myelination, diffuse white matter abnormalities, cerebellar atrophy, bilateral basal ganglia calcifications, and decreased choline and inositol peaks on magnetic resonance spectroscopy (34; 24; 22).

Management

Folate transport disorders. The most effective treatment of cerebral folate deficiency due to folate transport disorders has been oral 5-formyltetrahydrofolate, a 5-formyl derivative of tetrahydrofolic acid, which has been given the generic names of folinic acid (British-approved name) or leucovorin (United states-adopted name).

5-formyltetrahydrofolate is generally administered as calcium or sodium salt (eg, calcium folinate, sodium folinate, leucovorin calcium, leucovorin sodium). Treatment has been initiated with 0.5 to 1.0 mg/kg per day and in some cases has been increased to as high as 5 mg/kg per day. Treatment results in the normalization of folate concentrations in CSF and improvement of neurologic findings, even in patients with severe cerebral folate deficiency (37; 17; 30; 01; 43; 25; 20; 21; 23). Treatment with 5-formyltetrahydrofolate (folinic acid; leucovorin) can result in clinical improvement, but intravenous administration high-dose 5-formyltetrahydrofolate (folinic acid; leucovorin) may be necessary to control seizures and stop neurologic regression (11).

Treatment with folic acid is ineffective and may instead result in worsening seizures (40; 16; 47; 24).

A milk-free diet may be helpful for cerebral folate deficiency due to FOLR1 blocking or binding autoantibodies because this may help downregulate the production of FOLR1 autoantibodies (40).

Disorders of folate metabolism. Methylenetetrahydrofolate reductase deficiency is treated with betaine, folinic acid, or 5-methyltetrahydrofolate (32).

The small number of reported cases of dihydrofolate reductase deficiency improved with oral folinic acid supplementation, as demonstrated by improvement of CSF 5-MTHF levels, and improved seizure control and other neurologic symptoms (04; 09; 32).

Methenyl-tetrahydrofolate synthase deficiency is treated with 5-methyltetrahydrofolate and intramuscular methylcobalamin (32).

Outcomes

Individuals with cerebral folate deficiency due to folate transport disorders have usually responded to therapy with oral 5-formyltetrahydrofolate (folinic acid, leucovorin), a stable reduced folate derivative. It is probably critical to commence treatment before serious neurologic problems, such as developmental delay or visual and hearing loss, become established because they may not be readily reversible. In some cases, intravenous administration of high-dose 5-formyltetrahydrofolate (folinic acid; leucovorin) may be necessary to control seizures and stop neurologic regression (11).